You are here: Industry Insights > Bayer

News List

Bayer to Cut 12,000 Jobs americanpharmaceuticalreview
December 03, 2018
Bayer has announces multiple cost-cutting moves, including cutting 12,000 jobs of 118,200 worldwide, a significant number of them in Germany......
Bayer announces major restructure, 12,000 jobs to go pharmafile
December 03, 2018
Bayer has announced a major restructure of its operations in 2019 which will see the loss of 12,000 of its 118,200 positions following a number of lawsuits in the wake of its $63 billion buyout of agricultural biotech firm Monsanto.
Bayer Group Restructures contractpharma
December 03, 2018
Will result in the reduction of approximately 12,000 jobs worldwide by the end of 2021
NICE approves Bayer’s liver cancer drug pharmaphorum
November 30, 2018
NICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review following earlier guidance that rejected the drug......
EU gives Bayer's Jivi the green light November 29, 2018
Jivi (formerly BAY94-9027) has been approved by the European Commission for the treatment and prophylaxis of bleeding in previously treated patients 12 years of age or older...
Bayer's Jivi garners EU approval for treatment, prophylaxis of haemophilia A firstwordpharma
November 28, 2018
Bayer said Tuesday that the European Commission approved the recombinant Factor VIII (rFVIII) replacement therapy Jivi for the treatment and prophylaxis of bleeding in previously treated patients 12 years of age or older with haemophilia A. The therapy, f
Bayer’s Regorafenib is the First Drug to Enter GBM AGILE americanpharmaceuticalreview
November 19, 2018
The Global Coalition for Adaptive Research (GCAR) and Bayer announced that Bayers regorafenib will be the first drug to
Bayer Inc. receives approval for hemophilia A treatment Jivi firstwordpharma
October 25, 2018
Bayer Inc. receives approval for hemophilia A treatment Jivi
Bayer, Orion drug shows strong results in prostate cancer pharmatimes
October 25, 2018
Bayer and Orion's darolutamide, a novel oral androgen receptor antagonist for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC)...
Roche takes on Loxo, Bayer in gene-defined cancer class expressbpd
October 23, 2018
The Roche compound is designed to tackle several oncogenic mutations

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page